HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
6-ketoprostaglandin E1
potent direct dilator of pulmonary & systemic circulations of newborn lamb
Also Known As:
6-keto-PGE1; 6-keto-prostaglandin E1; 6-oxo-PGE1; 6-oxoprostaglandin E1
Networked:
12
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Lipids: 114793
Fatty Acids: 27405
Unsaturated Fatty Acids: 8236
Eicosanoids: 3262
Prostaglandins: 17100
Prostaglandins E: 2673
Alprostadil: 3107
6-ketoprostaglandin E1: 12
Monounsaturated Fatty Acids: 676
Alprostadil: 3107
6-ketoprostaglandin E1: 12
Biological Factors: 2472
Inflammation Mediators: 1113
Autacoids: 276
Eicosanoids: 3262
Prostaglandins: 17100
Prostaglandins E: 2673
Alprostadil: 3107
6-ketoprostaglandin E1: 12
Related Diseases
1.
Wounds and Injuries (Trauma)
04/01/1979 - "
In sham-operated rats, infusion of 6-keto-PGE1, at a rate of 250 ng/kg/min intravenously decreased arterial blood pressure by 23 mm Hg at 5 hr. In rats subjected to Noble-Collip drum trauma, infusion of 6-keto-PGE1, starting 15 min after the trauma, significantly improved the survival time from 1.0 +/- 0.1 to 2.6 +/- 0.3 hr compared to rats given only the vehicle (i.e., Tris buffer).
"
2.
Bone Resorption
07/01/1984 - "
The present study demonstrated that another metabolite of PGI2, 6-keto-prostaglandin E1 (6-keto-PGE1; also called 6-oxo-prostaglandin E1), was active in stimulating bone resorption in fetal rat long bone organ culture.
"
3.
Neoplasms (Cancer)
02/01/1985 - "
The mean survival time, median survival time, and increase of life survival percent (ILS%) during a 60 day period revealed that both 6-keto-pGE1 and 6-keto-pGE1 + MMC significantly inhibited AH-130 tumor cell growth, while TXB2 promoted tumor cell growth.
"
08/01/1984 - "
The mean survival days, median survival day, and ILS% for 60 days disclosed an inhibitory effect of 6-keto-PGE1, 6-keto-PGE1 + MMC on AH-130 tumor cell growth.
"
08/01/1984 - "
It is concluded that 6-keto-PGE1 which has a structure activity relationship with antitumor agents, such as MMC, Diketocoriolin B, etc., played an important inhibitory role in tumor cell growth in AH-130 in vivo, particularly in combination with the antitumor agents, MMC.
"
02/01/1985 - "
Three days after receiving an intraperitoneal injection of 3 X 10(6) AH-130 tumor cells, Donrhyu rats were injected intravenously or intraperitoneally with one of the following: Thromboxane B2 (TXB2) (0.5 mg/kg), 6-keto-pGE1 (0.5 mg/kg), Mitomycin C (MMC) (1.5 mg/kg), or MMC + 6-keto-pGE1 (1.5 mg/kg + 0.5 mg/kg).
"
02/01/1985 - "
We conclude that 6-keto-pGE1 like anti-tumor agents such as MMC, Diketocoriolin B, Carbazilquinon, Endoxan, and 5-Fluorouracil, can significantly inhibit growth of AH-130 tumor cells in vivo, particularly when administered in combination with the anti-tumor agent MMC.
"
4.
Hypotension (Low Blood Pressure)
02/15/1983 - "
These results indicate that 6-keto-PGE1 is similar to PGI2 in that it produces maternal cotyledonary vasoconstriction, hypotension, and vasodilation in other organs.
"
03/01/1988 - "
In six additional anesthetized dogs in which the carotid arteries were ligated in order to minimize baroreflexes, intracoronary injection of 6-keto-PGE1 and PGI2 (in doses of 7, 14 and 23 micrograms) caused systemic hypotension and bradycardia.
"
5.
Fever (Fevers)
07/01/1986 - "
Intrapreoptic injection of the prostacyclin metabolite, 6-keto-PGE1, produces pyrexia in the cat.
"
05/24/1988 - "
ED1 degrees doses (doses producing a 1 degree C fever) for PGE2, PGE1 and 6-keto-PGE1 (a metabolite of PGI2 and/or of the PGI2 hydrolysis product, 6-keto-PGF1 alpha) ranged between 2 and 15 pmol.
"
Related Drugs and Biologics
1.
Tromethamine (Trometamol)
2.
salicylhydroxamic acid (SHAM)
3.
Alprostadil (Muse)
4.
Dinoprostone (PGE2)
5.
Epoprostenol (Prostacyclin)
6.
diketocoriolin B
7.
Mitomycin (Mitomycin-C)
8.
6-Ketoprostaglandin F1 alpha (6 Ketoprostaglandin F1 alpha)
9.
Thromboxane B2
10.
Protein Kinases (Protein Kinase)
Related Therapies and Procedures
1.
Intraperitoneal Injections